Gast ::
| Hauptseite > Publikationsdatenbank > Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation > print |
| Hauptseite > Publikationsdatenbank > Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation > print |
| 001 | 844885 | ||
| 005 | 20220930130145.0 | ||
| 024 | 7 | _ | |a 10.3390/ijms19041090 |2 doi |
| 024 | 7 | _ | |a 1422-0067 |2 ISSN |
| 024 | 7 | _ | |a 1661-6596 |2 ISSN |
| 024 | 7 | _ | |a 2128/17954 |2 Handle |
| 024 | 7 | _ | |a pmid:29621181 |2 pmid |
| 024 | 7 | _ | |a WOS:000434978700169 |2 WOS |
| 024 | 7 | _ | |a altmetric:35753239 |2 altmetric |
| 037 | _ | _ | |a FZJ-2018-02231 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation |
| 260 | _ | _ | |a Basel |c 2018 |b Molecular Diversity Preservation International |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1523262053_15730 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Novel therapeutic targets in malignant glioma patients are urgently needed. Point mutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur predominantly in melanoma patients, but may also occur in gliomas. Thus, this is a target of great interest for this group of patients. In a nine-year-old male patient, an anaplastic astrocytoma in the left temporoparietal region was diagnosed histologically. After first- and second-line treatment, a malignant progression to a secondary glioblastoma was observed ten years after the initial diagnosis. Within the following seven years, all other conventional treatment options were exhausted. At this time point, recurrent tumor histology revealed an epithelioid glioblastoma, without a mutation in the isocitrate dehydrogenase gene (IDH wild-type). In order to identify a potential target for an experimental salvage therapy, mutational tumor analysis showed a BRAF V600E mutation. Consecutively, dabrafenib treatment was initiated. The patient remained clinically stable, and follow-up magnetic resonance images (MRI) were consistent with “Stable Disease” according to the Response Assessment in Neuro-Oncology Working Group (RANO) criteria for the following ten months until tumor progression was detected. The patient died 16 months after dabrafenib treatment initiation. Particularly in younger glioma patients as well as in patients with an epithelioid glioblastoma, screening for a V600E BRAF mutation is promising since, in these cases, targeted therapy with BRAF inhibitors seems to be a useful salvage treatment option. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Dunkl, Veronika |0 P:(DE-Juel1)156211 |b 2 |
| 700 | 1 | _ | |a Tscherpel, Caroline |0 P:(DE-Juel1)171739 |b 3 |u fzj |
| 700 | 1 | _ | |a Stoffels, Gabriele |0 P:(DE-Juel1)131627 |b 4 |u fzj |
| 700 | 1 | _ | |a Brunn, Anna |0 0000-0001-6233-8339 |b 5 |
| 700 | 1 | _ | |a Deckert, Martina |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Fink, Gereon Rudolf |0 P:(DE-Juel1)131720 |b 7 |u fzj |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 8 |e Corresponding author |u fzj |
| 773 | _ | _ | |a 10.3390/ijms19041090 |g Vol. 19, no. 4, p. 1090 - |0 PERI:(DE-600)2019364-6 |n 4 |p 1090 - |t International journal of molecular sciences |v 19 |y 2018 |x 1422-0067 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.pdf |
| 856 | 4 | _ | |x icon |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.gif?subformat=icon |
| 856 | 4 | _ | |x icon-1440 |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |x icon-180 |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-180 |
| 856 | 4 | _ | |x icon-640 |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-640 |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.pdf?subformat=pdfa |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.pdf |
| 856 | 4 | _ | |y OpenAccess |x icon |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.gif?subformat=icon |
| 856 | 4 | _ | |y OpenAccess |x icon-1440 |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y OpenAccess |x icon-180 |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y OpenAccess |x icon-640 |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-640 |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:844885 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)171739 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131627 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J MOL SCI : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a APC |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|